Finanzen von Immunome Inc (IMNM)IMNMImmunome Inc

Evaluating the bottom line, Immunome, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -64.03%, provide a clear picture of how effectively IMNM converts its operational activities into shareholder value.

In the context of the broader market, IMNM competes directly with industry leaders such as IRON and CLDX. With a market capitalization of $3.10B, it holds a significant position in the sector. When comparing efficiency, IMNM's gross margin of N/A stands against IRON's N/A and CLDX's 100.00%. Such benchmarking helps identify whether Immunome, Inc. is trading at a premium or discount relative to its financial performance.

Immunome has shown a significant increase in revenue, with Q2 2025 revenue at $4.015 million, up from $2.916 million in Q1 2025. However, it has been facing substantial net losses, with Q2 2026 net income at -$73.1 million. The gross margin has been consistently high at 100% until Q1 2026, where it dropped to 0%.